The radioprotective potential of the Bowman-Birk protease inhibitor is independent of its secondary structure

Cancer Letters

Volumn 125, Issue 1-2, 1998, Pages 77-82

  Gueven, Nuri ^a   Dittmann, Klaus ^a   Mayer, Claus ^a   Rodemann, H Peter ^a  

^a Sect for Radiobiol and Molec E   (Germany)

Author keywords

Bowman Birk protease inhibitor; Ionizing radiation; Protease; Radioprotection

Indexed keywords

BOWMAN BIRK INHIBITOR; CHYMOTRYPSIN; NONAPEPTIDE; PROTEINASE INHIBITOR; RADIOPROTECTIVE AGENT; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR;

ARTICLE; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; PROTEINASE INHIBITION; RADIATION PROTECTION; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELLS, CULTURED; HUMANS; PROTEIN STRUCTURE, SECONDARY; RADIATION-PROTECTIVE AGENTS; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032513277     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(97)00481-3     Document Type: Article

References (27)

1. Odani S., Ikenaka T. Scission of soybean Bowman-Birk proteinase inhibitor into two small fragments having either trypsin or chymotrypsin inhibitory activity. J. Biochem. 74:1973;857-860.
2. Odani S., Ikenaka T. Studies on soybean trypsin inhibitors. XIII. Preparation and characterization of active fragments from Bowman-Birk proteinase inhibitor. J. Biochem. 83:1978;747-753.
3. Maeder D.L., Sunde M., Botes D.P. Design and inhibitory properties of synthetic Bowman-Birk loops. Int. J. Peptide Protein Res. 40:1992;97-102.
4. Chen P., Rose J., Love R., Wei C.H., Wang B.C. Reactive sites of an anticarcinogenic Bowman-Birk proteinase inhibitor are similar to other trypsin inhibitors. J. Biol. Chem. 267(3):1992;1990-1994.
5. Billings P.C., St.Clair W., Ryan C.A., Kennedy A.R. Inhibition of radiation induced transformation of C3H/10T1/2 cells by chymotrypsin inhibitor 1 from potatoes. Carcinogenesis. 8:1987;809-812.
6. St.Clair W.H. Suppression of 3-methylcholanthrene-induced cellular transformation by timed administration of the Bowman-Birk protease inhibitor. Carcinogenesis. 12(5):1991;935-937.
7. St.Clair W.H., Billings P.C., Carew J.A., Keller-McGandy C., Newberne P., Kennedy A.R. Suppression of dimethylhydrazine-induced carcinogenesis in mice by dietary addition of the Bowman-Birk protease inhibitor. Cancer Res. 50:1990;580-586.
8. Billings P.C., Newberne P.M., Kennedy A.R. Protease inhibitor suppression of colon and anal gland carcinogenesis induced by dimethylhydrazine. Carcinogenesis. 11:1990;1083-1086.
9. von Hofe E., Newberne P.M., Kennedy A.R. Inhibition of N-nitrosomethylbenzylamine-induced esophageal neoplasms by the Bowman-Birk protease inhibitor. Carcinogenesis. 12(11):1991;2147-2150.
10. Kennedy A.R. Prevention of carcinogenesis by protease inhibitors. Cancer Res. 54(Suppl.):1994;1999-2005.
11. Dittmann K., Löffler H., Bamberg M., Rodemann H.P. Bowman-Birk proteinase inhibitor (BBI) modulates radiosensitivity and radiation induced differentiation of human fibroblasts in culture. Radiother. Oncol. 34:1995;137-143.
12. Lara P.C., Russel N.S., Smolders I.J.H., Bartelink H., Begg A.C., Cocomartin J.M. Radiation induced differentiation of human skin fibroblasts: relationship with cell survival and collagen production. Int. J. Radiat. Biol. 70:1996;683-692.
13. Rodemann H.P., Binder A., Burger A., Gueven N., Loeffler H., Bamberg M. The underlying mechanism of fibrosis. Kidney Int. 49:1996;S32-S36.
14. Bumann J., Santo-Höltje L., Loeffler H., Bamberg M., Rodemann H.P. Radiation induced alterations of the proliferation dynamics of human skin fibroblasts after repeated irradiation in the subtherapeutic dose range. Strahlenther. Oncol. 171:1995;35-41.
15. N. Gueven, K. Dittmann, H.P. Rodemann, Bowman-Birk protease inhibitor reduces the radiation-induced activation of the EGF-receptor and induces tyrosine phosphatase activity, Int. J. Radiat. Res. (1998), resubmitted.
16. Moy L.Y., Billings P.C. A proteolytic activity in a human breast cancer cell line which is inhibited by the anticarcinogenic Bowman-Birk protease inhibitor. Cancer Lett. 85:1994;205-210.
17. Billings P.C., Habres J.M. A growth-regulated protease activity that is inhibited by the anticarcinogenic Bowman-Birk protease inhibitor. Proc. Natl. Acad. Sci. USA. 89:1992;3120-3124.
18. Billings P.C., Habres J.M., Liao D.C., Tuttle W. Human fibroblasts contain a proteolytic activity which is inhibited by the Bowman-Birk protease inhibitor. Cancer Res. 51:1991;5539-5543.
19. Yavelow J., Caggana M., Beck K.A. Proteases occurring in the cell membrane: a possible cell receptor for the Bowman-Birk type of protease inhibitors. Cancer Res. 47:1987;1598-1601.
20. Oreffo V.I., Billings P.C., Kennedy A.R., Witschi H. Acute effects of the Bowman-Birk protease inhibitor in mice. Toxicology. 69:1991;165-176.
21. Madar Z., Birk Y., Gertler A. Native and modified Bowman-Birk trypsin inhibitor-comparative effect on pancreatic enzymes upon ingestion by quails. Comp. Biochem. Physiol. 48B:1974;251-256.
22. Birk Y. The Bowman-Birk inhibitor. Trypsin- and chymotrypsin-inhibitor from soybeans. Int. J. Peptide Protein Res. 25(2):1985;113-131.
23. Knebel A., Rahmsdorf H.J., Ullrich A., Herrlich P. Dephosphorylation of receptor tyrosine kinases as target of regulation by radiation, oxidants or alkylating agents. EMBO J. 15:1996;5314-5325.
24. Sachsenmaier C., Radler-Pohl A., Zinck R., Nordheim A., Herrlich P., Rahmsdorf H.J. Involvement of growth factor receptors in the mammalian UVC response. Cell. 78:1994;963-972.
25. Schmidt-Ullrich R.K., Valerie K., Fogleman P.B., Walters J. Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiat. Res. 145:1996;81-85.
26. J. Dunst, R. Sauer, Late Sequelae in Oncology, Springer, Berlin, 1995.
27. Kennedy C.W., Donahue J.J., Wan X.S. Effects of the Bowman-Birk protease inhibitor on survival of fibroblasts and cancer cells exposed to radiation and cis-platinum. Nutr. Cancer. 26(2):1996;209-217.